Immediate Impact
26 standout
Citing Papers
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
2025 Standout
Patient‐derived xenograft model in cancer: establishment and applications
2025 Standout
Works of M. Mauer being referenced
120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091
2023
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| M. Mauer | 77 | 49 | 111 | 14 | 137 | |
| Elodie Gaignard | 108 | 61 | 127 | 13 | 179 | |
| Samrat Kumar Mukherjee | 103 | 114 | 89 | 19 | 195 | |
| Toufik Bouhadiba | 51 | 34 | 85 | 18 | 128 | |
| Frederique L. Vissers | 112 | 75 | 88 | 16 | 159 | |
| C. Kettelhack | 57 | 32 | 37 | 11 | 143 | |
| Aydın Çiltaş | 39 | 60 | 40 | 16 | 137 | |
| G Pagano | 86 | 61 | 37 | 18 | 153 | |
| Adrian Lambert | 32 | 73 | 45 | 17 | 162 | |
| Marina Morais | 41 | 70 | 47 | 17 | 127 | |
| Sanne Lof | 177 | 156 | 118 | 17 | 228 |
All Works
Loading papers...